$BMY Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia

on June 11, 2021 News and Tags: , , , , , , , with 0 comments
Time:
3:00 AM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$XLRN Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021

on May 19, 2021 News and Tags: , , , with 0 comments
Time:
8:00 AM
Symbol:
XLRN
Source:
Business Wire News Releases
Read more

$XLRN Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress

on May 12, 2021 News and Tags: , , , with 0 comments
Time:
10:57 AM
Symbol:
XLRN
Source:
Business Wire News Releases
Read more

$XLRN Acceleron to Host Conference Call and Webcast to Review Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) Presented at the American Thoracic Soc

on May 11, 2021 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
XLRN
Source:
Business Wire News Releases
Read more

$XLRN Acceleron Announces First Quarter 2021 REBLOZYL® Net Sales

on April 29, 2021 News and Tags: , , , with 0 comments
Time:
7:10 AM
Symbol:
XLRN
Source:
Business Wire News Releases
Read more

$XLRN Acceleron to Webcast First Quarter 2021 Financial Results on May 6, 2021

on April 26, 2021 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
XLRN
Source:
Business Wire News Releases
Read more

$XLRN Acceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

on February 17, 2021 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
XLRN
Source:
Business Wire News Releases
Read more